If you take out the bio marker population the ORR was 10 percent. So while 15% is better than 10 it doesn’t seem like the agent is all that active regardless, unless they can find a further way to stratify responders I don’t follow the company but they must have shown more separation in earlier readouts between the targeted and total population but enough response in the total population to even bother to include them in this trial
The nominal deal value (excluding the CVR) is $129M. This acquisition is essentially a takeunder insofar as MRSN once had an enterprise value of about $3B.
Market Data 
Markets 
AI
